Steffen F. Nielsen

Arhus, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.

Explaining blood pressure reduction heterogeneity in sodium-glucose cotransporter-2 inhibitor trials: a meta-analysis stratified by patient characteristics.

Journal: Journal of hypertension

Published: March 19, 2026

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Journal: BMJ open

Published: February 26, 2026

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis.

Journal: BMJ open

Published: February 26, 2026

Renal effects of short-term ketone monoester supplementation in healthy adults: A randomized, placebo-controlled study.

Renal effects of short-term ketone monoester supplementation in healthy adults: A randomized, placebo-controlled study.

Journal: Physiological reports

Published: January 31, 2026

Dietary Sodium Reduction Reveals Aldosterone Dysregulation in Patients With Essential Hypertension.

Dietary Sodium Reduction Reveals Aldosterone Dysregulation in Patients With Essential Hypertension.

Journal: Journal of clinical hypertension (Greenwich, Conn.)

Published: October 27, 2025

Sodium reduction is the key ingredient in dietary treatment of hypertension - a randomized controlled trial on sodium, potassium and nitrate.

Sodium reduction is the key ingredient in dietary treatment of hypertension - a randomized controlled trial on sodium, potassium and nitrate.

Journal: Journal of human hypertension

Published: June 10, 2025

Empagliflozin and fluid balance: results from the SiRENA project.

Empagliflozin and fluid balance: results from the SiRENA project.

Journal: Clinical kidney journal

Published: May 05, 2025

The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis.

The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis.

Journal: American journal of hypertension

Published: January 17, 2025

The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials.

The effects of empagliflozin on systemic haemodynamic function: three randomized, placebo-controlled trials.

Journal: Journal of hypertension

Published: October 22, 2024

SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial.

SGLT2 inhibition improves endothelium-independent vasodilatory function in type 2 diabetes: A double-blind, randomized, placebo-controlled crossover trial.

Journal: Diabetes, obesity & metabolism

Published: September 11, 2024

Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD.

Pilot Study of Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Shows Reduced Intrarenal Complement Activation in Patients With Diabetes and CKD.

Journal: Kidney international reports

Published: August 27, 2024

Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin.

Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin.

Journal: Kidney international reports

Published: August 07, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026